Invokana Lawsuit 2026: the Closed MDL, the Amputation Warning That Stays & Whether You Can Still File

The Invokana lawsuits are not over, but the federal consolidation is. The multidistrict litigation that gathered hundreds of cases ended with no verdicts and no global settlement, while the FDA's amputation warning remains on the label today. Some law firms still review new claims in 2026, though filing has become much harder since the MDL closed.

Key Facts

  • Federal cases were consolidated as MDL No. 2750 in the District of New Jersey in December 2016 before Judge Brian R. Martinotti; 865 cases had been filed there by October 2017.
  • The MDL was later terminated with no verdicts and no settlements, according to case trackers — and no federal Invokana MDL is pending today.
  • The FDA required a boxed warning for leg and foot amputation risk on Invokana and Invokamet on May 16, 2017, based on the CANVAS and CANVAS-R trials; the boxed warning was removed in 2020 but the risk remains in the label's Warnings and Precautions.
  • The CANVAS trial showed amputations at about twice the rate of placebo: 5.9 per 1,000 canagliflozin patients versus 2.8 per 1,000 on placebo over one year.
  • Drugwatch's July 2026 litigation update states there were no verdicts or settlements in either the Invokana or Farxiga SGLT2 federal litigations.

What Is Invokana, and What Do the Lawsuits Allege?

An SGLT2 inhibitor is a class of type 2 diabetes drug that lowers blood sugar by making the kidneys flush glucose into the urine instead of reabsorbing it. Invokana — the brand name for canagliflozin, made by Janssen Pharmaceuticals, a Johnson & Johnson company — was the first drug of this class approved by the FDA, arriving in 2013. A companion product, Invokamet, combines canagliflozin with metformin.

The lawsuits allege that the manufacturer failed to adequately test the drug and to warn patients and doctors about serious risks. The injuries at the center of the claims include leg, foot, and toe amputations; diabetic ketoacidosis (a dangerous buildup of acids in the blood); kidney injury and kidney failure; and Fournier's gangrene, a rare flesh-eating infection of the genital area linked to the class in 2019 studies. The core legal argument is a failure-to-warn claim: the companies knew or should have known of these risks earlier and should have disclosed them on the label.

The MDL Story: 865 Cases In, No Trial Out

An MDL — multidistrict litigation — is a procedure that groups similar federal lawsuits before a single judge for pretrial handling. On December 7, 2016, a panel of judges transferred the federal Invokana cases to the District of New Jersey as MDL No. 2750, with 55 actions at transfer plus 44 related actions. By October 2017, 865 cases had been filed in that court.

Then the litigation quietly wound down. The MDL was terminated — case trackers place the closure with no federal Invokana MDL pending — and according to Drugwatch's July 1, 2026 update, there were no verdicts or settlements in either the Invokana or Farxiga federal litigations. For plaintiffs, this is the worst possible procedural outcome: years of consolidation produced no global deal, no test trial results, and no compensation fund. Each remaining claimant's path now depends on individual state-court filings or new legal theories.

The FDA Amputation Warning: Added in 2017, Removed in 2020 — and Still Relevant

A boxed warning is the FDA's strongest label warning, displayed in a black border on the drug's prescribing information. On May 16, 2017, the FDA required one for Invokana and Invokamet: final results from two large clinical trials, CANVAS (the Canagliflozin Cardiovascular Assessment Study) and CANVAS-R, showed leg and foot amputations occurring about twice as often in patients treated with canagliflozin as in those on placebo. Over a year, CANVAS showed 5.9 amputations per 1,000 canagliflozin patients versus 2.8 per 1,000 on placebo; CANVAS-R showed 7.5 versus 4.2 per 1,000. Toe and mid-foot amputations were most common, but below- and above-knee amputations also occurred, and some patients had more than one amputation, sometimes on both limbs.

In August 2020, the FDA removed the boxed warning after reviewing newer trial data that did not show the same excess risk. Crucially, the amputation risk did not disappear from the label — it remains in the Warnings and Precautions section to this day. For plaintiffs, this history cuts both ways: the removal undercuts the most dramatic version of the claim, but the original trial data and the years the boxed warning stood remain part of the record. Lawsuits must now argue that, given the patients most at risk, the warnings still did not come soon enough or go far enough.

The Other Injuries: Ketoacidosis, Kidney Damage, and Fournier's Gangrene

The litigation was never only about amputations. In 2015, the FDA warned that SGLT2 inhibitors could cause diabetic ketoacidosis and ordered strengthened warnings about bone fracture risk after reports accumulated. In 2016, after receiving more than 100 adverse-event reports — some involving life-threatening kidney failure — the FDA warned of acute kidney injury. In 2019, studies linked the class to Fournier's gangrene, a necrotizing infection that can become fatal within hours without emergency surgery.

The science is still moving. On May 28, 2025, researchers from the University of California, San Francisco published a study in JAMA Surgery of 7,439 surgical patients finding that SGLT2 inhibitors increased the risk of euglycemic diabetic ketoacidosis by 11% while simultaneously reducing acute kidney injury risk by 30% and lowering 30-day mortality. Nuanced results like these are why the lawsuits are fought claim by claim: the class is not a simple story of harm, and neither side gets to lean on a slogan.

Can You Still File an Invokana Claim in 2026?

Yes — but the landscape is far less favorable than it was in 2016. With no MDL pending and no settlement fund, new claimants cannot join a mass resolution. They must file individually, almost always in state court, and most firms accept these cases on contingency (the lawyer is paid a percentage of any recovery, so there is no upfront fee). Compensation varies widely by case, and most individual settlements are confidential.

The practical hurdles are real. Statutes of limitations vary by state and generally run from when the injury was discovered or should have been discovered, so delay can be fatal to a claim. The defendant will argue that the label did warn, that diabetes itself causes amputations, and that the boxed warning's removal proves the risk was overstated. A serious case needs a clear timeline: Invokana or Invokamet prescribed before the amputation, medical records tying the drug to the injury, and evidence that the prescribing doctor never warned of the risk.

What a Strong Invokana Case Needs

Lawyers evaluating new claims in 2026 look for a tight, documented chain. First, pharmacy records proving the prescription and fill dates. Second, medical records showing the amputation or injury and excluding other dominant causes. Third, evidence that the prescribing physician was not adequately informed — for example, prescriptions written before the 2017 boxed warning carry different weight than those written after. Fourth, timing that respects the state's deadline. Claims with all four elements get reviewed; claims missing the medical link usually do not get filed. If you believe you qualify, gather your records before speaking to a firm — the evaluation is free, but the records are what make it move.

Who Benefits From This — and Who Does Not

Who benefits most from this guide:

Patients who took Invokana or Invokamet and then suffered a leg or foot amputation. How: with no federal MDL pending, new claims must be filed individually, typically in state court, and most firms evaluate these cases on contingency, so there is no upfront fee.

Patients who suffered ketoacidosis, kidney damage, or Fournier's gangrene after taking the drug. How: these are the other injuries covered in this article, and they follow the same individual-filing path.

People with preserved prescription records and amputation documentation. How: a strong case needs the prescription history, the injury records, and timing that fits the warning history, including the boxed warning the FDA required on May 16, 2017.

Who does not benefit:

Anyone expecting to join a multidistrict litigation or a settlement fund. How: MDL No. 2750 was terminated with no verdicts and no settlements, and there is no settlement grid or announced payout schedule because no global deal was ever reached.

Anyone who took the drug with no injury and no prescription records. How: these claims need the drug, the injury, and records connecting them.

Anyone expecting a fast mass resolution. How: no global deal exists, so the only path is an individual state-court filing evaluated on its own evidence.

Another diabetes-drug litigation with a closed historic settlement is covered in our guide to the Actos lawsuit, where only narrow new paths remain.

Frequently Asked Questions

Is there still an Invokana MDL?

No. The federal multidistrict litigation, MDL No. 2750 in the District of New Jersey, was terminated with no verdicts and no settlements, and no federal Invokana MDL is pending. New claims must be filed individually, typically in state court.

Was there ever an Invokana settlement?

No. According to Drugwatch's July 2026 litigation update, there were no verdicts or settlements in either the Invokana or the Farxiga SGLT2 federal litigations.

Does Invokana still carry an amputation warning?

Yes. The FDA removed the boxed warning in 2020, but the risk of leg and foot amputation remains in the drug label's Warnings and Precautions section.

What compensation could an Invokana claim bring?

Compensation varies widely by case, and most settlements are confidential. There is no settlement grid or announced payout schedule because no global deal was ever reached. Most firms evaluate these cases on contingency, meaning no upfront fee.

Who can still file an Invokana claim?

Patients who took Invokana or Invokamet and then suffered an amputation, ketoacidosis, kidney damage, or Fournier's gangrene can still have an individual claim evaluated, typically in state court on contingency, even though no federal MDL is pending.

Who cannot join an Invokana settlement?

Nobody can join an Invokana settlement, because there is none: MDL No. 2750 was terminated with no verdicts and no settlements, and no global deal was ever reached, so there is no settlement grid or payout schedule.

Related Coverage

Drug injury litigation follows similar patterns across products. Read our 2026 update on the PPI kidney-injury lawsuits, the Suboxone October 2026 update with its first trial set, and the Elmiron update for how MDLs end differently. For visual explainers on how these cases work, see Problem Solved.

Disclaimer: This article is general information, not legal or medical advice. Lawsuit outcomes depend on individual facts and state law; consult a qualified attorney before acting.

Watch on YouTube

Problem Solved on YouTube